Primary Site >> Pancreatic Cancer
Gene >> CD33
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|
|
Ref: Emerging Therapies: Spectrum of Applications of Monoclonal Antibody Therapy. PMID: 11701553 |
Ref: Role of reactive oxygen species in brucein D-mediated p38-mitogen-activated protein kinase and nuclear factor-kappaB signalling pathways in human pancreatic adenocarcinoma cells. PMID: 20068565 |
Ref: Pancreatic tumors and immature immunosuppressive myeloid cells in blood and spleen: role of inhibitory co-stimulatory molecules PDL1 and CTLA4. An in vivo and in vitro study. PMID: 23359812 Ref: Pancreatic cancer-associated stellate cells promote differentiation of myeloid-derived suppressor cells in a STAT3-dependent manner. PMID: 23514705 Ref: The S100A8/A9 complex reduces CTLA4 expression by immature myeloid cells: Implications for pancreatic cancer-driven immunosuppression. PMID: 23894703 |
Ref: Increased levels of granulocytic myeloid-derived suppressor cells in peripheral blood and tumour tissue of pancreatic cancer patients. PMID: 24741628 |
Ref: Patients with pancreatic adenocarcinoma exhibit elevated levels of myeloid-derived suppressor cells upon progression of disease. PMID: 25305035 Ref: Inflammatory features of pancreatic cancer highlighted by monocytes/macrophages and CD4+ T cells with clinical impact. PMID: 25827621 |
Ref: Prognostic value of PDL1 expression in pancreatic cancer. PMID: 27589570 |
Ref: Surrogate in vitro activation of innate immunity synergizes with interleukin-7 to unleash rapid antigen-driven outgrowth of CD4+ and CD8+ human peripheral blood T-cells naturally recognizing MUC1, HER2/neu and other tumor-associated antigens. PMID: 27974697 |
Ref: [Prognostic value of tumor infiltration immune cells in pancreatic cancer]. PMID: 29886672 |